Orchard Grass Allergy: The Early-Blooming Grass That Catches You Off Guard
Orchard grass (Dactylis glomerata) is a Pooideae sweet grass that blooms earlier than timothy, initiating the grass pollen season in May when patients may not expect grass symptoms. Along with bluegrass, it drives more eastern US grass pollinosis in the first half of the season than all other grasses combined. It is one of five species in the Oralair SLIT tablet and shares approximately 95% cross-reactivity with timothy through Group 1 and Group 5 allergens.
Free · 5 min · Insurance accepted
Key facts
Orchard grass (Dactylis glomerata) blooms in May, initiating the grass pollen season 2–3 weeks before timothy — patients may not recognize early June nasal symptoms as grass allergy.
Orchard grass shares ~95% cross-reactivity with timothy through Group 1 and Group 5 allergens and is one of 5 species in the FDA-approved Oralair SLIT tablet.
Along with Kentucky bluegrass, orchard grass drives more eastern US grass pollinosis in the first half of the pollen season than all other grasses combined.
Orchard grass shows 76% antigenic similarity and 53% IgE-binding overlap with perennial ryegrass — one of the highest cross-reactivity scores among Pooideae grass pairs.
Starting intranasal corticosteroids in mid-April — 2 weeks before the May orchard grass peak — produces significantly better symptom control than initiating at first symptom onset.
Orchard grass (Dactylis glomerata) is a Pooideae cool-season grass distributed throughout the United States, with the exception of southern Florida and hot, dry lowlands.
It is widespread in meadows, roadsides, forest margins, and disturbed habitats, and is cultivated as a pasture and hay grass. Orchard grass is the sole species in its genus Dactylis — a botanical singularity that reflects its taxonomic distinctiveness within the Pooideae subfamily.
Like all Pooideae grasses, orchard grass shares approximately 95% IgE cross-reactivity with timothy, ryegrass, fescue, bluegrass, and sweet vernal grass through conserved Group 1 (beta-expansin) and Group 5 (ribonuclease-like) allergen proteins. Its WHO/IUIS-registered allergens follow the Dac g naming convention (Dac g 1, Dac g 5 homologs). This cross-reactivity means that laboratory tests using timothy components (Phl p 1, Phl p 5) reliably detect orchard grass sensitization, and timothy-based immunotherapy effectively treats orchard grass allergy.
Orchard grass is one of five grass species in Oralair — the FDA-approved 5-grass SLIT tablet — alongside timothy, bluegrass, ryegrass, and sweet vernal grass. Its inclusion in Oralair reflects its epidemiological importance as a primary early-season pollinosis driver and its 76% antigenic similarity and 53% IgE-binding overlap with ryegrass.
The clinical name orchard grass captures its original habitat association: it was historically found in the understory and margins of orchards, thriving in the partial shade and disturbed soil of agricultural edges. In modern suburban landscapes, it commonly grows along roadsides, fence lines, and utility rights-of-way — the unmown margins that many homeowners overlook when thinking about grass pollen exposure.
Recognizing symptoms early helps you get the right treatment faster.
When to see a doctor
Orchard grass allergy produces the same symptoms as other Pooideae grass allergies, consistent with shared allergen protein families driving cross-reactive IgE responses. **Upper respiratory symptoms (predominant):** - Paroxysmal sneezing, often in rapid multi-sneeze bursts - Profuse watery rhinorrhea - Nasal congestion and sinus pressure - Postnasal drip and throat clearing - Itching of the nose, palate, and inner ear **Ocular symptoms:** - Allergic conjunctivitis: itchy, red, watery eyes - Eyelid swelling and periocular edema - Photophobia during high-pollen periods **Lower respiratory (in sensitized individuals):** - Dry cough from postnasal drip - Wheezing and chest tightness in asthmatic patients - Exacerbation of pre-existing allergic asthma during May pollen peaks **Skin symptoms:** - Urticaria (hives) after direct contact with orchard grass - Contact dermatitis at exposure sites **Fatigue and quality-of-life impairment:** - Allergic fatigue from chronic histamine release and sleep disruption - Difficulty concentrating during symptomatic periods - Significant outdoor activity restriction during May–June A clinical feature to note: because orchard grass peaks in May while the public typically associates grass allergy with June, patients with early-season symptoms sometimes incorrectly attribute their symptoms to tree pollen finishing late (e.g., oak in late April/early May) or starting something new, rather than recognizing early grass sensitization. Skin prick testing with orchard grass extract or an early-season grass mix helps clarify the actual trigger.
Grass pollen is a well-established trigger for allergic asthma, and orchard grass's role in the eastern US spring pollinosis peak makes it one of the primary grass species associated with May asthma exacerbations in the northeastern and midwestern United States. The relationship between orchard grass and asthma follows the same mechanisms as other Pooideae grasses: IgE-mediated sensitization leads to early-phase bronchospasm on pollen exposure and late-phase eosinophilic inflammation that sustains airway hyperreactivity over hours to days. For patients with both allergic rhinitis and asthma, the nasobronchial reflex means that nasal mucosal inflammation from orchard grass pollen directly increases lower airway reactivity even at relatively low inhaled pollen doses. The timing dimension is clinically relevant for asthma management: patients who experience asthma exacerbations in May — before the commonly recognized peak of grass season — may have orchard grass as the driver. Controller medications adjusted only for the June timothy peak will leave a window of under-treatment in May when orchard grass pollen is at peak concentration. For individuals with asthma, initiating inhaled corticosteroid step-up or adding a short-acting beta-agonist rescue protocol before orchard grass season (late April) rather than at the conventional grass season start helps prevent the May asthma gap. The immunotherapy benefit for asthma is well-documented across Pooideae grasses — patients desensitized with grass SLIT tablets show reduced asthma symptom scores and reduced need for rescue bronchodilators during pollen season.
Untreated orchard grass allergy carries the same spectrum of complications as other grass pollen allergies, with an added dimension related to timing: **Early-season symptom gap:** Because orchard grass peaks before the conventionally recognized grass season, patients who treat only for June may leave their May symptoms untreated for years, accumulating unnecessary allergic inflammation during the orchard grass window. This repeated early-season inflammation contributes to lower airway sensitization and increases asthma risk. **Rhinitis-to-asthma progression:** As with all grass pollen allergies, untreated rhinitis is associated with a 30–40% risk of asthma development within 10 years. The early-season timing means orchard grass patients experience this risk starting in May rather than June. **Sinus complications:** Chronic nasal congestion from seasonal rhinitis promotes eustachian tube dysfunction and recurrent sinusitis. Patients who experience moderate May symptoms that resolve by July may not realize their annual sinus infections in June are a downstream consequence of untreated orchard grass allergy. **Oral allergy syndrome (OAS):** Grass-sensitized patients may experience OAS to raw foods including melon, tomato, orange, peach, and celery. Cross-reactive grass proteins are responsible for most grass-associated OAS. **Sensitization expansion:** Repeated high-dose seasonal exposures without treatment can drive new sensitivities — patients with isolated orchard grass allergy can develop weed, mold, or additional tree pollen sensitivities over subsequent seasons.
Orchard grass allergy is driven by IgE-mediated sensitization to its wind-dispersed pollen. When sensitized individuals inhale orchard grass pollen during the May–June peak, IgE antibodies on mast cells and basophils recognize Group 1 and Group 5 allergen proteins, triggering degranulation and release of histamine, prostaglandins, and leukotrienes. The result is the classical allergic rhinitis symptom cascade: sneezing, rhinorrhea, nasal congestion, and ocular irritation.
The primary allergen proteins in orchard grass are homologs of the universal Pooideae allergens: a Group 1 beta-expansin (corresponding to Phl p 1 in timothy) and Group 5 protein (corresponding to Phl p 5). The conserved structure of these proteins across the Pooideae subfamily is the molecular basis for cross-reactivity — a patient sensitized to orchard grass pollen produces IgE antibodies that recognize structurally equivalent epitopes on timothy, ryegrass, fescue, and bluegrass pollen.
The molecular similarity with ryegrass is notable: 53% IgE-binding overlap and 76% antigenic similarity. This is higher than the similarity between some other Pooideae pairs and helps explain why ryegrass and orchard grass together dominate the first half of eastern US grass season — their pollen seasons partly overlap, and their IgE cross-reactivity is nearly complete.
One distinctive exposure pathway for orchard grass is its prevalence along unmown road margins and field edges adjacent to residential areas. Many allergy sufferers focus avoidance efforts on maintained lawns while ignoring the dense orchard grass stands in highway verges, utility corridors, and park margins that can produce substantial local pollen loads. The timing of municipal mowing operations in late spring can also temporarily elevate local orchard grass pollen concentrations when large stands are disturbed simultaneously.
The Allergy Cascade
Exposure
Allergen contact
Detection
Immune recognition
IgE Response
Antibody production
Mast Cells
Histamine release
Symptoms
Allergic reaction
1.Exposure
Allergen contact
2.Detection
Immune recognition
3.IgE Response
Antibody production
4.Mast Cells
Histamine release
5.Symptoms
Allergic reaction
Diagnosing orchard grass allergy follows standard grass pollen allergy testing protocols, with an important nuance around early-season symptoms: **Skin prick testing (SPT):** Standardized orchard grass extract (Dactylis glomerata, FDA extract g3) is applied via lancet to the forearm. A wheal-and-flare reaction at 15–20 minutes confirms IgE-mediated sensitization. SPT with a grass mix panel typically includes orchard grass and will detect Dac g sensitization through cross-reactivity with the included grasses. **Serum IgE testing:** ImmunoCAP g3 (orchard grass-specific IgE) provides quantitative sensitization data. Because orchard grass is nearly completely cross-reactive with other Pooideae grasses, a positive grass mix or timothy test (ImmunoCAP g6) reliably indicates orchard grass sensitization as well. **Component-resolved diagnostics (CRD):** Phl p 1 and Phl p 5 testing identifies Pooideae sensitization and confirms that orchard grass is part of the patient's allergic profile. The absence of Cyn d 1 and negative Pas n 1 (for patients in Florida/Gulf Coast) confirm pure Pooideae sensitization without co-existing sour grass allergy. Curex offers at-home component testing using Phl p 1 and Phl p 5 panels to identify Pooideae sensitization, which includes orchard grass. For patients with May-onset grass symptoms, component testing helps distinguish early Pooideae pollen (orchard, bluegrass) from late-season tree pollen — an important distinction that determines optimal medication timing. **Clinical history:** Symptom onset in early May, before the peak timothy/bluegrass season, combined with residence in the eastern United States, strongly suggests orchard grass as the primary early-season trigger.
Test from home with Curex
Skip the clinic visit. Curex sends an at-home allergy test kit to your door, and a board-certified allergist reviews your results to build a personalized treatment plan.
Take the allergy quizThe long-term solution to allergies
Instead of masking symptoms, immunotherapy retrains your immune system.
Immunotherapy is the only disease-modifying treatment for grass allergy. For orchard grass allergy — a Pooideae sensitization — two FDA-approved SLIT tablets are available, with a key timing consideration: **Grastek (timothy grass SLIT tablet, 2800 BAU):** The sole FDA-approved single-grass SLIT tablet. Because orchard grass shares approximately 95% cross-reactivity with timothy through Group 1 and Group 5 allergens, Grastek effectively desensitizes orchard-grass-allergic patients. Approved for ages 5–65. Initiation must occur at least 12 weeks before grass season — for orchard grass patients with May symptoms, this means starting Grastek by February, earlier than the June-focused initiation schedule often cited in patient materials. **Oralair (5-grass SLIT tablet, 300 IR):** Explicitly includes orchard grass (Dactylis glomerata) as one of its five component grasses, alongside timothy, bluegrass, ryegrass, and sweet vernal. Approved for ages 10–65. Oralair may offer a marginal benefit for patients with high-density orchard grass-specific sensitization, though given 95% cross-reactivity, the clinical difference from Grastek is modest. **Subcutaneous immunotherapy (SCIT):** Injection-based immunotherapy with grass extract remains effective. Timothy-based extract covers orchard grass through cross-reactivity. **Curex custom SLIT drops** at **$39/month** provide multi-allergen convenience for patients with grass plus additional sensitivities (tree pollen, dust mites, weed pollen). A single daily drop formula can combine all sensitivities, and drops can be initiated earlier than the February Grastek-start constraint if needed for co-seasonal treatment — an important advantage given orchard grass's early May blooming.
Test & Diagnose
An at-home allergy test identifies your specific triggers with clinical-grade accuracy.
Custom Sublingual Drops
A personalized formula is created for your allergen profile, taken daily under the tongue.
Build Lasting Tolerance
Your immune system gradually learns to tolerate allergens, reducing symptoms over time.
Treat your Orchard Grass allergy at the source
See if at-home sublingual allergy drops fit your allergies — a 2-minute quiz, designed by board-certified allergists, with no needles and no clinic visits.
- 4.8/5Patient rating
- $79/moFinancing option
- 50K+Patients treated
- HSA/FSAEligible
Living With Orchard Grass Allergy
The dominant challenge of living with orchard grass allergy is the timing mismatch: most public allergy resources, weather apps, and casual advice calibrate to June as grass season, while orchard grass patients are already suffering in May. This mismatch results in delayed medication starts, incorrect attribution of symptoms to tree pollen, and inadequate preparation for what is often the most symptomatic part of the year. The practical adaptation for orchard grass patients is to mentally shift their internal allergy calendar one month earlier. Medication refills should happen in April. Pre-season INCS should start mid-April. Outdoor event planning should account for May pollen counts, not just June. Many orchard grass patients find significant relief simply from this calendar adjustment, after years of treating grass allergy correctly but starting a month too late. Work and school implications are worth addressing. May is often a high-stakes month — final exams, end-of-quarter reports, spring graduations — and orchard grass allergy can significantly impair cognitive function during this window. Students with documented orchard grass allergy should discuss accommodation timing with academic advisors; important assessments scheduled for May should be treated with the same proactive preparation as June allergy management. For outdoor enthusiasts, orchard grass is ubiquitous in the unmown margins of trails, parks, and recreational areas — the exact habitats many people use for spring fitness activities. Identifying high-orchard-grass areas on local trails, timing runs for early morning or rainy days, and keeping rescue medication accessible during outdoor exercise are practical habit adaptations. Immunotherapy substantially changes the experience for orchard grass patients. Moving to desensitization — knowing the May pollen season will be progressively less symptomatic each year — removes the anxiety of the annual timing scramble and the year-over-year symptom accumulation that characterizes untreated disease.
The natural history of untreated orchard grass allergy, like other grass pollen allergies, is persistence and gradual expansion rather than spontaneous resolution. Adults rarely outgrow grass pollen allergy. Most patients find that symptoms remain stable or worsen over years, and some experience expansion of the pollen season as new co-sensitizations develop to grasses with different peak times. With pharmacological management alone (antihistamines + INCS), symptoms are adequately controlled in many patients, but control is often imperfect during peak count days, and the underlying sensitization remains active. Patients on suppressive medication frequently find that their treatment requirements increase over successive seasons. Immunotherapy produces the only documented long-term modification of grass pollen allergy. Key outcomes from clinical trials: - Statistically significant reductions in symptom scores (total combined score reductions of 10–34% versus placebo for grass SLIT tablets) - Reduced rescue medication use during grass season - Sustained benefit extending through at least year 4 of treatment - Reduction in development of new sensitizations in monosensitized patients - In pediatric patients with allergic rhinitis, documented reduction in progression to asthma Real-world data mirror the trial results: in a Curex study of 2,897 patients on at-home sublingual immunotherapy, clinically meaningful symptom improvement rose to 45% of patients by two years, quality-of-life improvement reached 90.7%, adherence was over 90%, and no anaphylaxis was reported. For orchard grass allergy specifically, the prognosis with treatment is favorable because of the Pooideae cross-reactivity system: a single well-characterized immunotherapy (timothy-based, whether Grastek, Oralair, SCIT, or custom SLIT) desensitizes the immune response to orchard grass and five other common grass species simultaneously. Starting immunotherapy early in the disease course — at first recognition of grass allergy rather than after years of escalating symptoms — consistently yields the best long-term outcomes.
Orchard grass is the grass allergy that catches people off guard every May — they've been told their symptoms peak in June with timothy, but orchard grass starts the season earlier and can cause significant rhinitis before patients have started their seasonal medications.
Frequently Asked Questions
If your grass symptoms reliably begin in May, orchard grass is likely the primary culprit. Orchard grass (Dactylis glomerata) develops earlier in spring than timothy — the grass species that defines the standard grass allergy calendar — and it often produces its peak pollen in May, a month before timothy peaks in June. Along with Kentucky bluegrass, orchard grass accounts for more grass pollinosis in the eastern United States during the first half of the pollen season than all other grass species combined. The practical implication is that allergy medications and immunotherapy for orchard-grass-sensitive patients need to be timed to May onset, not the June start that most general allergy guidance describes. If you are starting intranasal steroids when you first notice symptoms in May, you have already missed the two-week pre-season window for optimal anti-inflammatory effect. Starting medications in mid-April typically produces significantly better May symptom control.
Yes — orchard grass is one of the five species explicitly included in Oralair, the FDA-approved 5-grass sublingual immunotherapy tablet. Oralair contains standardized extracts from orchard grass (Dactylis glomerata), timothy (Phleum pratense), Kentucky bluegrass (Poa pratensis), perennial ryegrass (Lolium perenne), and sweet vernal grass (Anthoxanthum odoratum). Grastek, the single-grass SLIT tablet standardized to timothy, also effectively treats orchard grass allergy through the approximately 95% IgE cross-reactivity between the Pooideae grasses. In practice, the clinical difference between Oralair (which includes orchard grass explicitly) and Grastek (which covers it via cross-reactivity) is modest for most patients. Both must be initiated at least 12 weeks before grass season — which for orchard-grass-sensitive patients means starting by February to be optimally effective for May pollen peaks.
Orchard grass is immunologically nearly identical to other Pooideae grasses — it shares approximately 95% IgE cross-reactivity with timothy, ryegrass, fescue, and bluegrass through conserved Group 1 and Group 5 allergen proteins. The meaningful clinical differences are ecological and temporal rather than immunological. First, timing: orchard grass blooms earlier than timothy and is the principal driver of May grass pollinosis, while timothy peaks in June and is the immunotherapy reference standard. Second, habitat: orchard grass is primarily found in unmown margins, roadsides, and field edges rather than maintained lawns, making it an exposure source patients often overlook. Third, taxonomic uniqueness: orchard grass is the sole species in genus Dactylis, making it botanically distinct despite its immunological similarity. In terms of treatment, orchard grass allergy is managed identically to timothy allergy — the same Grastek tablet, the same SCIT extracts, the same custom SLIT drops — because the immune response is functionally interchangeable.
Yes — new grass pollen sensitization can develop at any point in adulthood. While most grass allergies begin in childhood or adolescence, adult-onset grass allergy is well-documented and not uncommon. New sensitization can be triggered by increased cumulative pollen exposure (moving to a region with higher orchard grass density), a period of immune dysregulation, or the natural evolution of atopic disease in susceptible individuals. Patients who experience new May symptoms that they cannot attribute to prior exposures should consider grass skin testing or serum IgE testing to determine whether new Pooideae sensitization has developed. Because orchard grass blooms before the commonly recognized grass season, its role in new-onset May symptoms is frequently missed. Early diagnosis and early immunotherapy initiation in newly sensitized individuals consistently produces better long-term outcomes than waiting until symptoms become severe before seeking evaluation.
Hay fever — the colloquial term for seasonal allergic rhinitis — was originally named in the 19th century for the symptoms that agricultural workers experienced during hay-cutting season. Orchard grass is among the species most directly connected to the original hay fever concept: it is a hay crop, it is ready to cut before timothy (hence its role as the first grass that is cut in a mixed hay field), and its pollen peaks in May when traditional hay-cutting begins. In contemporary allergy medicine, hay fever refers broadly to seasonal allergic rhinitis from any pollen source, but orchard grass has a historically valid claim to being part of the original hay fever story. The symptoms — sneezing, rhinorrhea, itchy eyes, nasal congestion — are identical regardless of which Pooideae species drives them. For patients with May-onset hay fever in agricultural regions or areas with substantial unmown grassland nearby, orchard grass is a strong candidate for the primary trigger and should be included in allergy testing panels alongside timothy and ryegrass.
Managing orchard grass allergy during pregnancy requires balancing symptom control against medication safety, and it is best addressed in coordination with both an allergist and an obstetrician. Intranasal corticosteroids such as budesonide are generally considered the preferred first-line option for pregnant patients with allergic rhinitis, as they act locally with minimal systemic absorption. Loratadine and cetirizine are the oral antihistamines with the most established safety records in pregnancy, based on decades of human exposure data. Fexofenadine and first-generation antihistamines like diphenhydramine are used more cautiously. Immunotherapy already in progress before conception is typically continued through pregnancy, as the risk of anaphylaxis to dose escalation is avoided; initiating new immunotherapy during pregnancy is generally deferred until after delivery. Nasal saline rinses are entirely safe and reduce total allergen load. The key point is that untreated severe rhinitis can impair sleep, reduce oxygen saturation, and worsen quality of life — none of which is beneficial in pregnancy — so appropriate treatment is important rather than reflexive avoidance of all medications.
Several effective over-the-counter options are available for orchard grass allergy symptom management. Second-generation antihistamines — cetirizine (Zyrtec), loratadine (Claritin), and fexofenadine (Allegra) — are the most practical starting point for mild to moderate symptoms, causing less sedation than first-generation options like diphenhydramine. Intranasal corticosteroid sprays including fluticasone propionate (Flonase), triamcinolone (Nasacort), and budesonide (Rhinocort) are now available without a prescription and represent the most effective single-agent class for managing nasal symptoms; they require daily use for one to two weeks to reach full effect, so starting in mid-April is essential for patients with May orchard grass symptoms. Ketotifen eye drops (Zaditor, Alaway) provide effective OTC relief for allergic conjunctivitis. Nasal saline irrigation with a neti pot or squeeze bottle is a safe and effective adjunct that mechanically removes pollen from the nasal passages. For patients whose symptoms are not adequately controlled by OTC options, a prescription antihistamine, higher-dose INCS, or formal allergy evaluation with immunotherapy consideration is warranted.
Yes — cross-reactivity from orchard grass sensitization extends beyond airborne symptoms in two important ways. First, oral allergy syndrome (OAS): the Group 1 and Group 5 allergen proteins in orchard grass pollen share structural similarities with proteins in certain raw foods, including melon, raw tomato, orange, peach, celery, and kiwi. Eating these foods during peak orchard grass season can trigger localized mouth and throat itching or tingling that resolves within minutes. Cooking the foods eliminates the reaction in most cases. Second, occupational cross-exposure: individuals who work with ornamental grasses, in landscaping, or in agricultural hay production may experience more intense orchard grass exposure than their residential environment would suggest, because occupational grass handling during the May cutting season aerosolizes far more pollen than ambient outdoor air alone. Healthcare workers and others with delayed allergy recognition who work in high-exposure outdoor environments during May are at heightened risk for occupational sensitization or symptom worsening. Recognizing both the food cross-reactivity and occupational exposure dimensions leads to more complete allergy management than addressing only the airborne rhinitis component.
Medical References
- [1]Bousquet J, et al. Allergic Rhinitis and its Impact on Asthma (ARIA). Allergy. 2008;63(Suppl 86):8-160.
- [2]Nolte H, et al. Grastek (Timothy Grass Pollen Sublingual Tablet) Efficacy in Adults. J Allergy Clin Immunol Pract. 2015;3(3):393-401.
- [3]Pfaar O, et al. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis. Allergy. 2014;69(7):854-867.
- [4]Durham SR, Penagos M. Sublingual or subcutaneous immunotherapy for allergic rhinitis? J Allergy Clin Immunol. 2016;137(2):339-349.
- [5]Canonica GW, et al. A consensus update on the use of allergen immunotherapy in allergic rhinoconjunctivitis. Allergy. 2007;62(Suppl 84):1-58.
- [6]Demoly P, et al. Assessment of disease control in allergic rhinitis. Clin Transl Allergy. 2013;3(1):7.
- [7]Tharpe C, et al. Real-world outcomes of personalized sublingual immunotherapy for environmental allergies delivered through a telemedicine platform. Frontiers in Allergy. 2026;7:1865860.
- [8]Schaffer FM, Naples AR, Ebeling M, Hulsey TC, Garner LM. The safety of self-administered allergen immunotherapy during the buildup and maintenance phases. Int Forum Allergy Rhinol. 2015;5(2):149-156.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.
Ready to treat your Orchard Grass allergies for good?
Get a personalized treatment plan from board-certified allergists, delivered to your door.
Reviewed by board-certified allergists. Personalized treatment plans based on your at-home IgE test, not generic protocols.
Questions about Curex itself?
Straight answers about the company, the evidence, what patients report, and what it costs — including the parts that are not flattering.